News/ News/ Oncology Incyte makes bid to join the checkpoint inhibitor club Phil Taylor fda, immuno-oncology, Incyte, Oncology, Priority Review, retifanlimab 0 Comment Incyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal Share X Incyte makes bid to join the checkpoint inhibitor club https://pharmaphorum.com/news/incyte-makes-bid-to-join-the-checkpoint-inhibitor-club/
fda, immuno-oncology, Incyte, Oncology, Priority Review, retifanlimab
0 Comment
